Hindustan Agrigenetics Reports Profit in Q2 FY2026, Revenue Surges

Hindustan Agrigenetics Limited (ISIN: INE092301014) has reported a significant turnaround in its financial performance for the second quarter ended September 30, 2025. The company's board approved the unaudited financial results in a meeting held on November 14, 2025.

Key Financial Highlights

Metric	Q2 FY2026	Q1 FY2026	Change
Total Revenue	Rs 32.13 lacs	Rs 8.09 lacs	+297.20%
Profit After Tax	Rs 16.85 lacs	Rs -40.19 lacs (Loss)	Turned Profitable
Cash and Cash Equivalents	Rs 5,38,13,854	Rs 5,14,05,088	+4.70%

Revenue Growth and Profitability

Hindustan Agrigenetics has demonstrated a remarkable improvement in its financial performance. The company's total revenue surged to Rs 32.13 lacs in Q2 FY2026, a substantial increase from Rs 8.09 lacs in the previous quarter. This represents a growth of 297.20% quarter-on-quarter.

Turnaround in Profitability

The most notable aspect of the results is the company's shift from loss to profit. Hindustan Agrigenetics reported a profit after tax of Rs 16.85 lacs for Q2 FY2026, compared to a loss of Rs 40.19 lacs in the previous quarter. This turnaround indicates a significant improvement in the company's operational efficiency and market performance.

Improved Liquidity Position

The company's cash and cash equivalents increased to Rs 5,38,13,854 from Rs 5,14,05,088, showing a 4.70% improvement in its liquidity position. This enhancement in cash reserves provides the company with more financial flexibility for future operations and investments.

Corporate Governance Compliance

Hindustan Agrigenetics, in its LODR filing, stated that the provisions of Corporate Governance under SEBI regulations are not applicable to the company. This is because the company's paid-up capital does not exceed Rs. 10 Crore, and its Net Worth does not exceed Rs. 25 Crore based on the audited financial statements as of March 31, 2025.

Conclusion

The Q2 FY2026 results mark a positive shift for Hindustan Agrigenetics Limited, with significant improvements in revenue and profitability. The company has successfully turned its operations around, moving from a loss-making position to profitability within a quarter. While these results are encouraging, investors and stakeholders should continue to monitor the company's performance in the coming quarters to assess the sustainability of this growth trajectory.

The financial results were reviewed by Anant Rao & Mallik, Chartered Accountants, who found no material misstatements in the unaudited financial results prepared in accordance with applicable Indian Accounting Standards.

Hindustan Agrigenetics Limited, a company listed on the Bombay Stock Exchange (BSE: 519574), has undergone significant leadership changes following a successful open offer. The company has announced several key appointments and resignations, reshaping its board structure and leadership team.

Board Changes

The following changes have been made to the company's board:

Mrs. Vidya Jonnalagadda appointed as a woman Independent Director
Five board members resigned:
- Mrs. Chandani Kapur
- Mr. Sunny Srivastava
- Mr. Naren Parsai
- Mr. Pranav Kapur
- Ms. Mannu Kohli
Mr. Pritam Kapur tendered his resignation but was requested to continue as Managing Director until December 15, 2025
Mr. Rajendra Naniwadekar will take over as Managing Director from December 15, 2025

New Committee Formation

The company has formed three statutory committees:

Audit Committee: Chaired by P.K. Rambabu
Nomination and Remuneration Committee: Chaired by Ravi Shankar Kolathur
Stakeholders Relationship Committee: Chaired by Shashank Vaidya

About Dr. Vidya Jonnalagadda

Dr. Vidya Sobhianaditya Jonnalagadda brings a wealth of experience to her new role:

Aspect	Details
Experience	Over 40 years in biology research and teaching
Education	PhD from University of Pennsylvania, Philadelphia, PA
Research Background	Worked at prestigious institutions including Indian Institute of Science (Bangalore), Fox Chase Cancer Center (Philadelphia), Center for Cellular and Molecular Biology (Hyderabad), Osmania University (Hyderabad), and Massachusetts Institute of Technology (Cambridge, MA)
Teaching Experience	Transitioned to teaching about 20 years ago
Specialization	Genetics, molecular biology, virology, and immunology at undergraduate and post-graduate levels

Appointment Details

The company has provided the following information regarding Dr. Jonnalagadda's appointment:

Aspect	Details
Appointment Date	October 18, 2025
Position	Non-Executive Independent Director
DIN	06685501
Relationship with Other Directors	None
Regulatory Status	Not a willful defaulter, not barred by SEBI or any other regulator

Corporate Governance

Hindustan Agrigenetics Limited has emphasized that Dr. Jonnalagadda's appointment aligns with regulatory requirements. The company has confirmed that the appointee has no relationships with existing directors and meets all necessary regulatory criteria.

The Board meeting where these decisions were made commenced at 5:00 pm (IST) and concluded at 5:45 pm (IST) on October 18, 2025. The appointments and changes are in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These strategic changes to the Board and leadership team, including Dr. Jonnalagadda's extensive background in biology and research, could potentially bring valuable insights to Hindustan Agrigenetics Limited, a company operating in the agrigenetics sector. Shareholders will have the opportunity to approve these appointments in an upcoming General Meeting.